Cross-trial analysis of immunological and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax®) in colorectal, renal and prostate cancer patients

被引：0
|
作者：
Harrop, R. [1 ]
Shingler, W. H. [1 ]
Drury, N. [1 ]
Goonewardena, M. [1 ]
de Belin, J. [1 ]
Naylor, S. [1 ]
Treasure, P. [1 ]
机构：
[1] Peter Treasure Stat Serv Ltd, NA, Cambridge, England
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72535-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：188 / 188
页数：1
相关论文
共 50 条
  • [1] Cross-trial Analysis of Immunologic and Clinical Data Resulting From Phase I and II Trials of MVA-5T4 (TroVax) in Colorectal, Renal, and Prostate Cancer Patients
    Harrop, Richard
    Shingler, William
    Kelleher, Michelle
    de Belin, Jackie
    Treasure, Peter
    JOURNAL OF IMMUNOTHERAPY, 2010, 33 (09) : 999 - 1005
  • [2] Analysis of immunological and clinical data resulting from four phase I and II trials of MVA-5T4 in colorectal cancer patients
    Harrop, R.
    Shingler, W. H.
    Goonewardena, M.
    de Belin, J.
    Kelleher, M.
    Drury, N.
    Treasure, P.
    Naylor, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial
    Harrop, Richard
    Chu, Franklin
    Gabrail, Nashat
    Srinivas, Sandy
    Blount, Daniel
    Ferrari, Anna
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (09) : 1511 - 1520
  • [4] Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4)
    Eyad Elkord
    Adam Dangoor
    Deborah J. Burt
    Thomas D. Southgate
    Sai Daayana
    Richard Harrop
    Jan W. Drijfhout
    David Sherlock
    Robert E. Hawkins
    Peter L. Stern
    Cancer Immunology, Immunotherapy, 2009, 58 : 1657 - 1667
  • [5] Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4)
    Elkord, Eyad
    Dangoor, Adam
    Burt, Deborah J.
    Southgate, Thomas D.
    Daayana, Sai
    Harrop, Richard
    Drijfhout, Jan W.
    Sherlock, David
    Hawkins, Robert E.
    Stern, Peter L.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (10) : 1657 - 1667
  • [6] Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer
    Amato, Robert J.
    Stepankiw, Mika
    FUTURE ONCOLOGY, 2012, 8 (03) : 231 - 237
  • [7] Vaccination of castration-resistant prostate cancer patients with TroVax (MVA–5T4) in combination with docetaxel: a randomized phase II trial
    Richard Harrop
    Franklin Chu
    Nashat Gabrail
    Sandy Srinivas
    Daniel Blount
    Anna Ferrari
    Cancer Immunology, Immunotherapy, 2013, 62 : 1511 - 1520
  • [8] MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial
    Scurr, Martin
    Pembroke, Tom
    Adams, Richard
    Blount, Daniel
    Brewster, Alison
    Gwynne, Sarah
    Harrop, Richard
    Jones, Robert
    Hills, Robert
    Gallimore, Awen
    Godkin, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07)
  • [9] TRIST: A randomised, double blind, placebo controlled phase III study of MVA-5T4 in metastatic renal cancer patients
    Hawkins, R.
    Harrop, R.
    Naylor, S.
    Easty, S.
    McDonald, M.
    Tomczak, C.
    Szczylik, C.
    Amato, R.
    EJC SUPPLEMENTS, 2009, 7 (03): : 11 - 11
  • [10] TRIOC-A randomised phase II trial to examine MVA-5T4 vaccine in patients with relapsed asymptomatic epithelial ovarian, fallopian tube or primary peritoneal cancer
    Michael, A.
    Wilson, W.
    Harrop, R.
    McNeish, I.
    Lord, R.
    Blount, D.
    Clamp, A. R.
    Feeney, M.
    Farrelly, L.
    Hanna, L.
    Kristeleit, R.
    Nicum, S.
    Walther, A.
    Pressey, O.
    Hackshaw, A.
    Ledermann, J. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S629 - S629
12345